Logo
x

Search

Subscribe Now

Obstructive Hypertrophic Cardiomyopathy

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

  • May 17, 2021
BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Clinical and RWE Data of Mavacamten for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

  • May 4, 2021
BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

BMS Reports the US FDA's Acceptance of NDA for Mavacamten to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

  • March 22, 2021
BMS Highlighted Long-Term Follow-Up Results from Two P-III Studies of Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    BMS Highlighted Long-Term Follow-Up Results from Two P-III Studies of Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopa...

    • August 29, 2023
    BMS’ Camzyos (mavacamten) Receives EC’s Approval for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

      BMS’ Camzyos (mavacamten) Receives EC’s Approval for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

      • June 27, 2023
      BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic Cardiomyopathy

        BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic Cardiomyopathy

        • June 2, 2023
        BMS Receives EMA’s CHMP Positive Opinion Recommending Approval of Camzyos (mavacamten) for Symptomatic Obstructive Hypertrophic Cardiomyopathy

          BMS Receives EMA’s CHMP Positive Opinion Recommending Approval of Camzyos (mavacamten) for Symptomatic Obstructive Hypertrophic Ca...

          • April 27, 2023
          LianBio Reports the NMPA Acceptance of NDA and Granted Priority Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy

            LianBio Reports the NMPA Acceptance of NDA and Granted Priority Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy

            • April 24, 2023
            BMS Reports Results of Mavacamten in P-III (VALOR-HCM) Study for the Treatment of Obstructive Hypertrophic Cardiomyopathy

              BMS Reports Results of Mavacamten in P-III (VALOR-HCM) Study for the Treatment of Obstructive Hypertrophic Cardiomyopathy

              • February 17, 2022
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.